Sage Therapeutics SAGE announced that its board of directors has rejected the unsolicited, non-binding proposal offer from ...

Sage Therapeutics has a unique approach to targeting GABA, which allows it to target CNS disorders. Its main asset is Zurzuvae, which is co-marketed with Biogen for PPD. BIIB recently made a bid ...

After receiving and considering an "unsolicited" buyout offer from partner Biogen, Sage Therapeutics is kicking the tires on a range of strategic options. However, the company's board of directors ...

Mizuho raised the firm’s price target on Sage Therapeutics (SAGE) to $9 from $6 and keeps a Neutral rating on the shares. The firm reassessed ...

Sage Therapeutics announced its boards unanimous rejection of Biogens $469 million acquisition offer, stating the proposal ...

Sage Therapeutics rejected a takeover offer from Biogen (BIIB) and said it started a process to review its strategic alternatives. Sage rose 5.6%. Sage's board will look at a range of ...

Sage Therapeutics, Inc. filed an 8-K report with the Securities and Exchange Commission. The filing disclosed that the Board of Directors of Sage Therapeutics has commenced a strategic review process ...

Securities adjusted its outlook on Sage Therapeutics (NASDAQ:SAGE) shares, with analyst Vamil Divan increasing the price target to $9.00 from the previous $6.00, while maintaining a Neutral rating on ...

January 27, 2025--(BUSINESS WIRE)--Sage Therapeutics, Inc. (Nasdaq: SAGE) ("Sage" or "the Company"), today announced that its Board of Directors has initiated a process to explore strategic ...

In a report released today, Uy Ear from Mizuho Securities maintained a Hold rating on SAGE Therapeutics (SAGE – Research Report), with a price ...

Sage Therapeutics has brought a lawsuit against Biogen shortly after receiving an “unsolicited” offer from its neuroscience partner. The lawsuit is sealed in Delaware’s Court of Chancery ...